** Shares of Solid Biosciences SLDB.O rises 51.9% to $6.12
** Co says its experimental gene therapy for a rare muscle wasting disorder was well-tolerated in 6 participants dosed in an early-stage study
** Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene, which interferes with the production of proteins needed to form healthy muscles
** Says no serious adverse events were observed
** Also says that some patients showed significant improvements in multiple muscle health biomarkers
** Separately, co's 35.7 mln stock offering priced at $4.03 each, which was the last closing price of its shares
** SLDB has fallen ~56% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.